Instrument Inactif

Autres langues LYSOGENE

Actions

LYS

FR0013233475

Recherche biotechnologique et médicale

Autres langues

10/10/23	Fragile X Syndrome Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
18/09/23	Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)
06/07/23	Lysogene S.A.(ENXTPA:LYS) dropped from CAC AllShares Index
06/07/23	Lysogene S.A.(ENXTPA:LYS) dropped from Next Biotech Index
14/06/23	Lysogene CFO Assumes Same Role at Mauna Kea Technologies
29/05/23	Lysogene to Delist from Euronext amid Judicial Liquidation
02/05/23	Bolsa de Madrid: First Republic muerde el polvo a su vez
29/04/23	LYSOGENE : Inside Information / News release on accounts, results
29/04/23	Lysogene S.A. Announces Postponement of 2022 Financial Results Release
17/04/23	Lysogene Fails to Secure Takeover Bid Amid Reorganization
06/02/23	French Gene Therapy Group Lysogene Makes Ad Interim CFO Permanent
03/02/23	Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer
09/01/23	Bolsa de Madrid: No hace falta mucho para ser feliz
07/12/22	Lysogene Seeks Launch of Safeguard Process Amid Financing Woes
06/12/22	LYSOGENE : Inside Information / Operations of the issuer (acquisitions, sales...)
30/11/22	Lysogene : Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis
21/11/22	Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday November 23, 2022
21/11/22	Bolsa de Madrid: La parte trasera entre dos sillas
18/11/22	Lysogene Provides Updates and Topline Results from Phase 2/3 Aavance Gene Therapy Clinical Study
18/11/22	LYSOGENE : Inside Information / Other news releases
26/09/22	Bolsa de Madrid: El elefante en la habitación
23/09/22	Lysogene S.A. Reports Earnings Results for the Half Year Ended June 30, 2022
16/09/22	Lysogene Announces New Board of Directors
11/07/22	LYSOGENE : Half-year liquidity contract statement for LYSOGENE
07/07/22	Lysogene's Gene Therapy Improves Cognitive, Motor Functions In Initial Phase 2/3 Data